ArticleLipids in health and disease2026
Dietary restriction genes as modulators of breast cancer risk through metabolic pathways.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBreast cancer is a highly heterogeneous disease shaped by both genetic predispositions and environmental influences. While substantial advancements have been achieved in treatment, issues such as tumor recurrence and resistance to therapy continue to hinder effective, personalized prevention strategies. Dietary restriction—a modifiable lifestyle factor—has shown promise in cancer prevention by influencing metabolic pathways and immune function. Nevertheless, the contribution of genes associated with dietary restriction to breast cancer susceptibility remains largely unclear.
methodsDifferential expression analysis of 276 dietary restriction-related genes, including 1,080 breast cancer samples and 99 normal controls, was conducted using RNA sequencing data from The Cancer Genome Atlas. To assess the causal relationships between dietary restriction genes and metabolic indicators (LDL HDL, BMI, WC, and TG), genetic variants associated with these indicators were examined. Protein‒protein interaction networks were constructed to identify key interactions, and potential therapeutic compounds were predicted through the DSigDB database. Molecular docking was subsequently performed to evaluate the binding affinities between these compounds and the proteins encoded by dietary restriction-related genes.
resultsA total of 86 dietary restriction-related genes were significantly associated with breast cancer, with seven shared SNP loci identified in conjunction with metabolic indicators, providing evidence of a potential causal relationship. KEGG and GO enrichment analyses revealed that these genes regulate longevity pathways and lipid metabolism, influencing breast cancer development. PPI analysis revealed core regulatory nodes, and drug prediction highlighted several candidate compounds, including perfluoroundecanoic acid and rifampicin, with strong binding affinities to dietary restriction-related proteins. In vitro experiments demonstrated that perfluoroundecanoic acid has protective effects against breast cancer oncogenesis.
conclusionsThis study suggests a potential causal relationship between dietary restriction-related genes and breast cancer, revealing their significant association with tumour development and metabolic regulation and identifying perfluoroundecanoic acid as a candidate for further investigation in breast cancer prevention. These findings offer new insights for precision prevention strategies and adjunct lifestyle-based clinical management in patients with breast cancer, contributing to the broader goal of reducing the global burden of this prevalent disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.